Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Oral mucositis is a gastrointestinal inflammation that can cause several problems in the human body. It can affect the general nutritional intake of a person. Oral mucositis is a common health issue arising from cancer treatment and other factors. It causes several problems that include pain, nutritional problems as a result of inability to eat, and an increased risk of infection due to open sores in the mucosa.

The U.S. Severe oral mucositis Market is estimated to be valued at US$ 78.5 Mn in 2021 and is expected to exhibit a CAGR of 19.2% during the forecast period (2021-2028).

Figure 1.U.S. Severe Oral Mucositis Market Share (%) in Terms of Value, By Drug Type, 2021

U.S. Severe Oral Mucositis  | Coherent Market Insights

Increasing prevalence of head and neck cancer in the U.S. is expected to drive the market growth during the forecast period.

The increasing prevalence of head and neck cancer is a primary driving factor for the growth of the U.S. severe oral mucositis market over the forecast period. According to the American Society of Clinical Oncology (ASCO)’s 2021 report, approximately 4% of individuals suffered from head and neck cancer in the U.S. and an estimate of 66,630 people (48,740 men and 17,890 women) were expected to develop head and neck cancer.

request-sample

U.S. Severe Oral Mucositis Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 78.5 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2020 to 2027
Forecast Period 2021 to 2028 CAGR: 19.2% 2028 Value Projection: US$ 267.7 Mn
Geographies covered:
  • North America: U.S.
Segments covered:
  • By Drug Type: Palifermin, Amifostine, Chlorhexidine, Sucralfate, Late Phase (Avasopasem and Dusquetide)
  • By Cause: Chemotherapy, Radiotherapy
  • By Grade: Grade III, Grade IV
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group.

Growth Drivers:
  • Increasing prevalence of head and neck cancer in the U.S.
  • Key players focusing on inorganic strategies and fund raising activities
Restraints & Challenges:
  • High incremental cost associated with severe oral mucositis in cancer patients

Figure 2 .U.S. Severe Oral Mucositis Market Share (%), by Cause, 2021

U.S. Severe Oral Mucositis  | Coherent Market Insights

Key players are focusing on inorganic strategies and fund raising, which is expected to drive the market growth during the forecast period.

The key players in the U.S. are focusing on fund raising activities for boosting research and development for the treatment of severe oral mucositis caused due to radiation and chemotherapy in the cancer patients. For instance, in September 2018, Galera Therapeutics, Inc., a company developing novel mechanism-based therapies, announced that the company secured US$ 150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, and Tekla Capital Management LLC. The existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures, and Sofinnova Ventures also participated.

U.S. Severe Oral Mucositis Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products, and affected the growth of several oral mucositis medication businesses of various companies across the regions such as North America (U.S.). COVID-19 pandemic led to an unprecedented lockdown in several countries such as U.S. This lockdown resulted in closure of industrial establishments except manufacturing of essential commodities and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by various governments in the past few months, while countries such as Brazil, France, Russia, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Due to severe shortage of medical resources at the front line, only patients diagnosed with serious conditions are being hospitalized. Unfortunately, the pathogenic mechanism of the virus has not been identified completely, even though, vaccines and drugs are being manufactured by various companies for prevent and treat COVID-19. The COVID-19 pandemic has impacted the global economy and in turn, the U.S. severe oral mucositis market. Quarantine, traveling constraints, and social distancing measures are likely to cause a steep decline in business and consumer spending until the end of the first quarter of 2021.

U.S. Severe Oral Mucositis Market: Restraint

The major factors that hinder growth of the U.S. severe oral mucositis market include high incremental cost associated with severe oral mucositis in cancer patients. For instance, according to the report published by Oxford University Press in 2019, patients undergoing chemotherapy and radiation therapy for the treatment of head and neck cancers have to pay incremental cost for the treatment of complications associated with the treatments such as severe oral mucositis. According to the same source, patients have to pay extra US$ 5,000– 30,000 for the treatment of oral mucositis that was induced due to radiation therapy while patients had to pay US$ 3,700 per cycle for oral mucositis induced due to chemotherapy in the U.S. This treatment cost included hospitalization fees, medication cost (medications included are kepivance (Palifermin), analgesic drugs, and systemic infusions in severe cases, among others), and others.

Key Players

Major players operating in the U.S. severe oral mucositis market are Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group

Oral mucositis refers to tissue swelling in the mouth. Radiation therapy or chemotherapy may cause mucositis. Oral mucositis is an erythematous and ulcerative lesion of the oral mucosa observed in patients with cancer who are treated with chemotherapy, and/or with radiation therapy. Lesions of oral mucositis are often very painful and compromise nutrition and oral hygiene as well as increase the risk for local and systemic infection. Oral mucositis is a significant and dose-limiting toxicity of cancer therapy with important clinical and economic implications. Oral mucositis from chemotherapy or radiation treatment can last from 7 to 98 days.

Market Dynamics

The key players in the market are focused on growth strategies such as FDA approvals, which are expected to drive the growth of the market over forecast period. For instance, in November 2016, Oragenics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AG013, the company’s lead therapeutic candidate for the treatment of oral mucositis. Furthermore, in April 2018, Enzychem Lifesciences announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EC-18 for the treatment of chemo-radiation induced oral mucositis. Moreover, key companies focusing on research and development of severe oral mucositis are expected to drive the growth of the market over forecast period. For instance, in December 2019, Oragenics, Inc., announced the completion of enrolment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, which is an easy-to-use oral rinsing system designed to prevent and treat oral mucositis.

Key features of the study:

  • This report provides in-depth analysis of the U.S. severe oral mucositis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. severe oral mucositis market based on the following parameters – Company Highlights, financial performance, product portfolio, market presence, distribution strategies, Key Highlights, strategies, and future plans
  • Key companies covered as a part of this study include Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S. severe oral mucositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. severe oral mucositis market.

Detailed Segmentation:

  • U.S. Severe Oral Mucositis Market, Drug Type:
    • Palifermin
    • Amifostine
    • Chlorhexidine
    • Sucralfate
    • Late Phase (Avasopasem, Dusquetide)
  • U.S. Severe Oral Mucositis Market, By Cause:
    • Chemotherapy
    • Radiotherapy
  • U.S. Severe Oral Mucositis Market, By  Grade:
    • Grade III
    • Grade IV
  • U.S. Severe Oral Mucositis Market, By  Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Hospital
  • Company Profiles
    • Innovation Pharmaceuticals Inc. *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Monopar Therapeutics Inc.
    • Soligenix, Inc.
    • Oragenics, Inc.
    • Enzychem Lifesciences
    • Galera Therapeutics, Inc.
    • Amgen, Inc.
    • Covis Pharma Group

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Cause
      • Market Snapshot, By Grade        
      • Market Snapshot, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Key Developments
    • Treatment Approaches
    • Merger, Acquisitions & Agreements
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Pricing Analysis & Brand Analysis
    • Therapeutics Overview: (Route of Administration/Dosage Forms, Dosage Regimen, etc.)
    • Epidemiology
  4. U.S. Severe Oral Mucositis Market– Impact of Coronavirus (COVID-19) Pandemic
    • Impact on Supply and Demand
    • Impact Clinical Trial
    • Government Initiatives
  5. U.S. Severe Oral Mucositis Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018– 2028
      • Segment Trends
    • Palifermin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Amifostine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Chlorhexidine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Sucralfate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Late Phase (Avasopasem and Dusquetide)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  6. U.S. Severe Oral Mucositis Market, By Cause, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Radiotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  7. U.S. Severe Oral Mucositis Market, By Grade, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Grade III
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Grade IV
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  8. U.S. Severe Oral Mucositis Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  9. Competitive Landscape
    • Heat Map Analysis
    • Competitive Snapshot
    • Company Profiles
      • Innovation Pharmaceuticals Inc.*
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Monopar Therapeutics Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Soligenix, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Oragenics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Enzychem Lifesciences
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Galera Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Amgen, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Covis Pharma Group
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
  10. 10, 11 & 12 Section
    • Research Methodology
    • About Us & Services
    • Contact

*Browse 12 market data tables and 22 figures on "U.S. Severe Oral Mucositis Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The U.S. severe oral mucositis market size is estimated to be valued at US$ 78.5 Mn in 2021 and is expected to exhibit a CAGR of 19.2% between 2021 and 2028.
Factors such as increasing prevalence of head and neck cancer in the U.S. and inorganic strategies and fund raising activities by key players are expected to drive the market growth during the forecast period.
Palifermin segment is expected to hold a major market share in market in 2021.
The major factors hampering growth of the market include high incremental cost associated with severe oral mucositis in cancer patients.
Major players operating in the market are Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.